Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ginsberg

Showing results (271-280 of 312) with videos related to

Pageof 32
Sort By:
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Diabetes Care|December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes AssociationJohn B Buse, Henry N Ginsberg, George L Bakris, et al.
Journal of Alzheimer'S Disease : JAD|August 30, 2021
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled TrialJeffrey Cummings, Gregory G Schwartz, Stephen J Nicholls, et al.
The Journal of Biological Chemistry|August 27, 2014
Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failureLi Liu, Chad M Trent, Xiang Fang, et al.
Journal of the American College of Cardiology|January 13, 2018
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic StenosisSotirios Tsimikas, Sergio Fazio, Keith C Ferdinand, et al.
JAMA|August 29, 2017
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular RiskBrian A Ference, John J P Kastelein, Henry N Ginsberg, et al.
The American Journal of Cardiology|July 12, 2007
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods, John B Buse, J Thomas Bigger, et al.
The Journal of Biological Chemistry|December 30, 2016
Normalization of Hepatic Homeostasis in the <i>Npc1</i> Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor VorinostatAndrew B Munkacsi, Natalie Hammond, Remy T Schneider, et al.
Rapid Communications in Mass Spectrometry : RCM|May 18, 2013
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometryHaihong Zhou, Jose Castro-Perez, Michael E Lassman, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
Pageof 32

Showing results (271-280 of 312) with videos related to

Sort By:
Pageof 32
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Diabetes Care|December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes AssociationJohn B Buse, Henry N Ginsberg, George L Bakris, et al.
Journal of Alzheimer'S Disease : JAD|August 30, 2021
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled TrialJeffrey Cummings, Gregory G Schwartz, Stephen J Nicholls, et al.
The Journal of Biological Chemistry|August 27, 2014
Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failureLi Liu, Chad M Trent, Xiang Fang, et al.
Journal of the American College of Cardiology|January 13, 2018
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic StenosisSotirios Tsimikas, Sergio Fazio, Keith C Ferdinand, et al.
JAMA|August 29, 2017
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular RiskBrian A Ference, John J P Kastelein, Henry N Ginsberg, et al.
The American Journal of Cardiology|July 12, 2007
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods, John B Buse, J Thomas Bigger, et al.
The Journal of Biological Chemistry|December 30, 2016
Normalization of Hepatic Homeostasis in the <i>Npc1</i> Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor VorinostatAndrew B Munkacsi, Natalie Hammond, Remy T Schneider, et al.
Rapid Communications in Mass Spectrometry : RCM|May 18, 2013
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometryHaihong Zhou, Jose Castro-Perez, Michael E Lassman, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
Pageof 32